Fever and survival with drug-treated non-small cell lung cancer

3Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Patients with non-small cell lung cancer who develop fever during anti-neoplastic chemotherapy are treated empirically, before the cause of fever has been determined. Little study has been made of episodes of infection during chemotherapy with respect to antineoplastic response, other adverse reactions, or survival time. In particular, the relationship between fever and long-term survival is not clear. The prognostic significance of febrile episodes was investigated in patients with non-small cell lung cancer receiving full-dose chemotherapy. Most were treated only with chemotherapy during the period of investigation, although some had concurrent or subsequent radiotherapy, and a few had surgery following chemotherapy. No significant difference was seen between febrile and afebrile patients regarding therapeutic modality. Patients with poor performance status (PS) had a higher incidence of febrile episodes (P

Cite

CITATION STYLE

APA

Ide, S. (2001). Fever and survival with drug-treated non-small cell lung cancer. Kurume Medical Journal, 48(1), 9–14. https://doi.org/10.2739/kurumemedj.48.9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free